|
所属 |
附属病院 腫瘍内科 |
|
ホームページ |
出身大学 【 表示 ／ 非表示 】
-
2007年04月-2011年03月
秋田大学 医学部 医学科 卒業
-
2001年04月-2005年03月
東京工業大学 理学部 生命科学科生命情報コース 卒業
出身大学院 【 表示 ／ 非表示 】
-
2014年04月-2019年03月
秋田大学 医学系研究科 医学専攻 腫瘍制御医学系 臨床腫瘍学講座 博士課程 修了
-
2005年04月-2007年03月
東京大学 新領域創成科学研究科 メディカルゲノム専攻 修士課程 修了
職務経歴（学内） 【 表示 ／ 非表示 】
-
2022年04月-継続中
秋田大学 附属病院 腫瘍内科 特任助教
-
2019年04月-2022年03月
秋田大学 医学部 寄附講座 寄附講座助教
研究経歴 【 表示 ／ 非表示 】
-
FN1をターゲットにした腫瘍血管新生阻害活性
（選択しない）
研究期間：
2019年04月-継続中研究態様：個人研究
研究課題概要
癌細胞パネルを用いた化合物ライブラリーのスクリーニングから抗腫瘍活性が強化されたクルクミン類縁体を得た。200種類超える類縁体の中に、クルクミンを50倍以上凌駕する活性化合物（GO-Y030, 078）などが含まれていた。このうちGO-Y078には血管新生阻害活性が存在することを見出した（Anticancer Agents Med Chem. 2016）。そのメカニズムは血管内皮増殖因子（VEGF）を阻害するものではなかった。現在、VEGFを標的とした癌分子標的療法が一定の成功を収めている。しかし、耐性の問題や腫瘍血管新生のリダンダンシーの問題があり、十分な効果を上げているとは言い難い。クルクミン類縁体による血管新生阻害療法耐性打破の方法を解明し、臨床応用を目指す。
学位論文 【 表示 ／ 非表示 】
-
Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors.
Shimazu K, Inoue M, Sugiyama S, Fukuda K, Yoshida T, Taguchi D, Uehara Y, Kuriyama S, Tanaka M, Miura M, Nanjyo H, Iwabuchi Y, Shibata H
Cancer science 109 ( 10 ) 3285 - 3293 2019年03月
単著
研究等業績 【 表示 ／ 非表示 】
-
Fujita K.
Investigational New Drugs ( Investigational New Drugs ) 42 ( 3 ) 252 - 260 2024年06月
研究論文（学術雑誌）
The aim of the present study was to determine whether the trough plasma concentrations (C0) of regorafenib and its metabolites, the N-oxide metabolite (M-2) and the desmethyl N-oxide metabolite (M-5), in 21 patients receiving regorafenib therapy were affected by albumin-bilirubin (ALBI) grade. Regorafenib was administered at dosages ranging from 40 to 160 mg once daily on a 3-week-on, 1-week-off cycle. C0 values of regorafenib and its major metabolites were measured by high-performance liquid chromatography on day 8 after treatment initiation. The C0 values of regorafenib and metabolites M-2 and M-5 were significantly lower in patients with ALBI grade 2 as compared with grade 1 (P = 0.023, 0.003 and 0.017, respectively). The total C0 of regorafenib and its metabolites was significantly higher in ALBI grade 1 patients relative to grade 2 (3.489 μg/mL vs. 1.48 μg/mL; P = 0.009). The median relative dose intensity (RDI) of patients categorized as ALBI grade 2 was significantly lower than that of grade 1 patients (21.9% vs. 62.9%; P = 0.006). In 15 colorectal cancer patients among the total 21 patients, patients with ALBI grade 2 (n = 9) had a significantly shorter median overall survival time than patients with grade 1 (n = 6; P = 0.013). Administering a low dose of regorafenib to patients with ALBI grade 2 reduces the RDI of regorafenib and lowers treatment efficacy, as an appropriate C0 of regorafenib is not maintained. Monitoring the C0 of regorafenib regularly is necessary to guide dose adjustment.
-
Recent trends in bone metastasis treatments: A historical comparison using the new Katagiri score system.
Kenji Matsuda, Kazuhiro Shimazu, Hanae Shinozaki, Koji Fukuda, Taichi Yoshida, Daiki Taguchi, Kyoko Nomura, Hiroyuki Shibata
World journal of clinical cases 12 ( 15 ) 2499 - 2505 2024年05月
研究論文（学術雑誌）
BACKGROUND: Bone metastasis has various negative impacts. Activities of daily living (ADL) and quality of life (QOL) can be significantly decreased, survival may be impacted, and medical expenses may increase. It is estimated that at least 5% cancer patients might be suffering from bone metastases. In 2016, we published the Comprehensive Guidelines for the Diagnosis and Treatment of Bone Metastasis. Since then, the therapeutic outcomes for patients have gradually improved. As life expectancy is a major determinant of surgical intervention, the strategy should be modified if the prolongation of survival is to be achieved. AIM: To monitor how bone metastasis treatment has changed before and after launch of our guidelines for bone metastasis. METHODS: For advanced cancer patients with bone metastasis who visited the Department of Clinical Oncology at Akita University hospital between 2012 and 2023, parameters including the site and number of bone metastases, laboratory data, and survival time, were extracted from electronic medical records and the Katagiri score was calculated. The association with survival was determined for each factor. RESULTS: Data from 136 patients were obtained. The 1-year survival rate for the poor prognosis group with a higher Katagiri score was 20.0% in this study, which was 6% and an apparent improvement from 2014 when the scoring system was developed. Other factors significantly affecting survival included five or more bone metastases than less (P = 0.0080), and treatment with chemotherapy (P < 0.001), bone modifying agents (P = 0.0175) and immune checkpoint inhibitors (P = 0.0128). In recent years, advances in various treatment methods have extended the survival period for patients with advanced cancer. It is necessary not only to simply extend survival time, but also to maintain ADL and improve QOL. CONCLUSION: Various therapeutic interventions including surgical approach for bone metastasis, which is a disorder of locomotor organs, are increasingly required. Guidelines and scoring system for prognosis need to be revised promptly.
-
Taguchi D, Inoue M, Fukuda K, Yoshida T, Shimazu K, Fujita K, Okuyama H, Matsuhashi N, Tsuji A, Yoshida K, Miura M, Shibata H
International Journal of Clinical Oncology 2019年12月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors.
Shimazu K, Inoue M, Sugiyama S, Fukuda K, Yoshida T, Taguchi D, Uehara Y, Kuriyama S, Tanaka M, Miura M, Nanjyo H, Iwabuchi Y, Shibata H
Cancer science 109 ( 10 ) 3285 - 3293 2018年08月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Guillain-Barré syndrome in a cancer patient treated with bevacizumab.
Taguchi D, Kamada S, Yoshida T, Fukuda K, Shimazu K, Inoue M, Sugawara M, Nanjyo H, Iijima K, Shibata H
International Cancer Conference Journal 2018年05月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Akahira R.
Japanese Journal of Clinical Oncology ( Japanese Journal of Clinical Oncology ) 54 ( 2 ) 201 - 205 2024年02月
-
Kiyomiya M.
Japanese Journal of Clinical Oncology ( Japanese Journal of Clinical Oncology ) 53 ( 3 ) 270 - 274 2023年03月
-
Mounai Y.
Case Reports in Oncology ( Case Reports in Oncology ) 16 ( 1 ) 21 - 29 2023年01月
-
Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome.
Tomohiro Matsumoto, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Daiki Taguchi, Hanae Shinozaki, Katsuhito Seki, Takayuki Yamanaka, Mako Ootaka, Hiroshi Nanjyo, Hiroyuki Watanabe, Hiroyuki Shibata
International cancer conference journal 11 ( 1 ) 81 - 86 2022年01月
Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte associated antigen-4 inhibitors, and inhibitors of programmed cell death 1 and its ligand, are widely used in the treatment of several malignant tumors. Immune-related adverse events occur in two-thirds of recipients. Among them, cardiotoxicities are very rare (about 1%), albeit fatal. Pembrolizumab-induced cardiotoxicity in a patient was successfully treated with high-dose corticosteroids, and his cardiac function was maintained by adrenergic drugs and intra-aortic balloon pumping in the intensive care unit for 1 week. Cardiotoxicity with ICIs is an oncologic emergency, and should be managed in a pluridisciplinary setting involving cardiologists.
-
Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry
Kato Y.
Case Reports in Oncology ( Case Reports in Oncology ) 15 ( 1 ) 21 - 26 2022年01月